Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic (OTCMKTS:BVNRY) was the recipient of a significant decline in short interest in September. As of September 15th, there was short interest totaling 833 shares, a decline of 44.7% from the August 31st total of 1,506 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 1,944 shares, the short-interest ratio is presently 0.4 days.

Bavarian Nordic Trading Down 1.6%

BVNRY traded down $0.18 during trading on Thursday, hitting $10.81. 217 shares of the company’s stock were exchanged, compared to its average volume of 3,168. Bavarian Nordic has a 1 year low of $8.67 and a 1 year high of $13.00. The stock has a 50 day moving average price of $10.22 and a 200 day moving average price of $9.86. The firm has a market cap of $2.57 billion, a P/E ratio of 10.92 and a beta of 1.20.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its earnings results on Friday, August 21st. The company reported $0.46 EPS for the quarter. The business had revenue of $316.47 million for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%.

About Bavarian Nordic

Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.

Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.